newsfilter
← Latest News
Business Wire·

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV Topline Results Anticipated in 3Q'26 Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage